

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Morton Grove Pharmaceuticals, Inc.		03/01/2009	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Wockhardt EU Operations (Swiss) AG
Street Address:	Baarerstrasse 43
City:	6300 Zug
State/Country:	SWITZERLAND
Entity Type:	CORPORATION: SWITZERLAND

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Serial Number:	76316866	BROMAXEFED
Serial Number:	76316944	CARBAXEFED
Serial Number:	76316865	C-PHED TANNATE
Serial Number:	73604183	MYPHETANE
Serial Number:	74352326	MYTUSSIN
Serial Number:	76344188	PHENCLOR TANNATE
Serial Number:	76316867	PYRILAFEN TANNATE-12
Serial Number:	76117057	TANNIHIST-12

CORRESPONDENCE DATA

Fax Number: (312)993-9767
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: (312) 876-7700
 Email: thomas.buettner@lw.com
 Correspondent Name: Thomas J. Buettner
 Address Line 1: Latham & Watkins LLP

OP \$215.00 76316866

Address Line 2: 233 S. Wacker Drive, Suite 5800
Address Line 4: Chicago, ILLINOIS 60606

ATTORNEY DOCKET NUMBER: 045401-0001

DOMESTIC REPRESENTATIVE

Name:
Address Line 1:
Address Line 2:
Address Line 3:
Address Line 4:

NAME OF SUBMITTER: Thomas J. Buettner

Signature: /tjb/

Date: 04/21/2009

Total Attachments: 3
source=Morton Grove Pharmaceuticals Trademark Assignment#page1.tif
source=Morton Grove Pharmaceuticals Trademark Assignment#page2.tif
source=Morton Grove Pharmaceuticals Trademark Assignment#page3.tif

TRADEMARK ASSIGNMENT

This TRADEMARK ASSIGNMENT (this "Trademark Assignment") is made effective as of March 1, 2009 by Morton Grove Pharmaceuticals, Inc., a Delaware corporation ("Assignor") to Wockhardt EU Operations (Swiss) AG, a Swiss corporation ("Assignee").

WITNESSETH:

WHEREAS, Assignor and Assignee have entered into that certain Intellectual Property Sale Agreement, dated as of March 1, 2009 (the "IP Sale Agreement");

WHEREAS, Assignor is the owner of each of the trademarks and trademark applications (including any and all goodwill symbolized thereby) set forth on Schedule A attached hereto and made a part hereof, together with all registrations and applications for registration thereof, all common law rights with respect thereto, and all rights to sue and recover for past, present and future infringement thereof (the "Product Trademarks");

WHEREAS, pursuant to the IP Sale Agreement, Assignee wishes to acquire, and Assignor wishes to transfer to Assignee, Assignor's entire right, title and interest in and to the Product Trademarks and the goodwill related thereto; and

WHEREAS, Assignee and Assignor desire to record the assignments set forth in this Trademark Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, it is hereby agreed that:

1. Conveyance and Acceptance. Assignor hereby assigns, transfers and conveys to Assignee, Assignor's entire right, title and interest in and to the Product Trademarks including, but not limited to, all benefits, privileges, causes of action, and remedies relating to such Product Trademarks, including, without limitation, the exclusive rights to (a) apply for and maintain all registrations, renewals and/or extensions thereof, (b) bring actions and recover damages for past, present and future infringement thereof, (c) grant licenses or other interests therein and (d) otherwise fully and entirely stand in the place of Assignor in all matters related thereto. The foregoing includes, and Reliant hereby assigns, transfers and conveys to Assignee, all goodwill symbolized by the Product Trademarks. Assignee accepts such assignment and assumes (and shall pay, perform and discharge when due) all obligations with respect to such Product Trademarks from and after the date of this Trademark Assignment.


2. Further Action. Assignor agrees, at Assignee's expense, to do all acts and take such further action, including the execution and acknowledgement of such additional documents as Assignee may reasonably request to carry out and fulfill the purposes and intent of this Trademark Assignment.

Signature page follows.

IN WITNESS WHEREOF, Assignor has caused this Trademark Assignment to be executed by its duly authorized representative as of the date first written above.

ASSIGNOR:

Morton Grove Pharmaceuticals, Inc.

By: 

Name: Kurt Orlofski

Title: President

Schedule A

Product Trademarks

Trademarks

Mark	App. No.	App. Date	Reg. No.	Reg. Date
BROMAXEFED	76/316,866	9/25/01	2,886,986	9/21/04
CARBAXEFED	76/316,944	9/25/01	2,767,636	9/23/03
C-PHED TANNATE	76/316,865	9/25/01	2,733,086	7/1/03
MYPHETANE	73/604,183	6/13/86	1,423,581	1/6/87
MYTUSSIN	74/352,326	1/25/93	1,810,428	12/14/93
PHENCLOR TANNATE	76/344,188	10/30/01	2,725,672	6/10/03
PYRILAFEN TANNATE-12	76/316,867	9/25/01	2,744,001	7/29/03
TANNIHIST-12	76/117,057	8/25/00	2,643,928	10/29/02